{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:04:17Z","timestamp":1753877057241,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Salvage surgery following immunotherapy is a promising treatment option for advanced malignant tumour. However, only a few cases of salvage surgery for malignant pleural mesothelioma (MPM) have been reported. This retrospective study was conducted to assess the feasibility of salvage surgery following immunotherapy for initially unresectabele MPM. Among 61 patients who received pleurectomy\/decortication (P\/D) for MPM, 7 patients received salvage P\/D after immunotherapy. Surgical indication of salvage P\/D was conversion to resectability in 5 patients and local relapse in 2 patients, and macroscopic complete resection was achieved in all patients. Although salvage P\/D was associated with longer operation time (median, 507\u2009min), higher intraoperative blood loss (median, 2573\u2009mL) and higher morbidity (\u2265 grade 3, 29%), no patient died after surgery. Radiographic response to immunotherapy was well correlated with pathologic response, as all 4 patients with partial response showed significant pathologic response (viable cells, \u226450%). With the median postoperative follow-up duration of 9.0\u2009months, all patients were alive mostly without tumour recurrence as local recurrence developed in 1 patient. To conclude, salvage P\/D after immunotherapy may be a feasible treatment option for selected patients with advanced MPM, which should be validated in future multi-institutional studies. In addition, a long-term follow-up is essential to reveal the clinical benefit achieved with salvage P\/D following immunotherapy.<\/jats:p>","DOI":"10.1093\/icvts\/ivad173","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T06:07:14Z","timestamp":1699942034000},"source":"Crossref","is-referenced-by-count":1,"title":["Salvage pleurectomy\/decortication following immunotherapy for malignant pleural mesothelioma"],"prefix":"10.1093","volume":"38","author":[{"given":"Masaru","family":"Takenaka","sequence":"first","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuma","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Mori","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Taira","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Kuwata","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"2024021117593011100_ivad173-B1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"2024021117593011100_ivad173-B2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"2024021117593011100_ivad173-B3","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024021117593011100_ivad173-B4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2020.12.037","article-title":"Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment","volume":"153","author":"Ohtaki","year":"2021","journal-title":"Lung Cancer"},{"key":"2024021117593011100_ivad173-B5","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/j.cllc.2022.05.002","article-title":"Salvage surgery after immune checkpoint inhibitors for advanced non-small cell lung cancer: potential association between immune-related adverse events and longer survival","volume":"23","author":"Nagata","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2024021117593011100_ivad173-B6","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/j.athoracsur.2022.01.011","article-title":"Salvage resection after immunotherapy in refractory malignant pleural mesothelioma","volume":"114","author":"Banks","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2024021117593011100_ivad173-B7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atssr.2022.07.004","article-title":"Salvage pleurectomy\/decortication after immunotherapy for sarcomatoid malignant pleural mesothelioma","volume":"1","author":"Kajiyama","year":"2023","journal-title":"Ann Thorac Surg Short Rep"},{"key":"2024021117593011100_ivad173-B8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s11748-021-01643-z","article-title":"Non-incisional pleurectomy\/decortication for malignant pleural mesothelioma","volume":"69","author":"Tanaka","year":"2021","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2024021117593011100_ivad173-B9","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J Clin Oncol"},{"key":"2024021117593011100_ivad173-B10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.athoracsur.2021.04.078","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication for malignant pleural mesothelioma","volume":"113","author":"Zhou","year":"2022","journal-title":"Ann Thorac Surg"}],"container-title":["Interdisciplinary CardioVascular and Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/icvts\/advance-article-pdf\/doi\/10.1093\/icvts\/ivad173\/53420112\/ivad173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/38\/2\/ivad173\/56660132\/ivad173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/38\/2\/ivad173\/56660132\/ivad173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T17:59:44Z","timestamp":1707674384000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/icvts\/article\/doi\/10.1093\/icvts\/ivad173\/7421916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/icvts\/ivad173","relation":{},"ISSN":["2753-670X"],"issn-type":[{"type":"electronic","value":"2753-670X"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,11,15]]},"article-number":"ivad173"}}